BOTHELL, Wash., July 9 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has engaged InCap Group, Inc. (InCap) to provide strategic investment and financial advice and services. CellCyte seeks to build shareholder value by monetizing its two core platform technologies and will work with InCap to initiate a corporate partnering strategy to exploit development and commercialization of CellCyte's cell expander and stem cell delivery technologies.
"We are committed to realizing the value in our two stem cell enabling technologies and look forward to the counsel InCap can provide in this regard as well as their assistance in executing staged capital raises," said Gary A. Reys, President and CEO of CellCyte.
"The promise of stem cells in regenerative medicine has been hampered by the inability to generate sufficient cells and the lack of effective non-invasive ways to deliver them to the therapeutic target. CellCyte's two technology platforms may provide the solutions to both of these fundamental problems. We are excited about helping the Company commercialize its highly leveraged technologies," noted Paul J. Marangos, Ph.D., a consultant with InCap.
CellCyte's strategic initiatives include:
-- Transitioning from a research to a commercialization business approach
-- Establishing a partnering strategy targeting multiple companies involved in the clinical exploitation of stem cells
-- Accelerating the development and commercialization of the company's
cell expander bioreactor technology
-- Staged milestone driven capital formation
About InCap Group
InCap Group, Inc., is an investment banking firm focused on the
investment management and securities brokerage industries. They provide
merger and acquisition services, capital raising services, valuations and
strategic advice to their clients. The value of their services is derived
from the market experience of
|SOURCE CellCyte Genetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved